SSC
HZNP

Syverson Strege & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Syverson Strege & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25
Closed -$2.73K – 663
2023
Q1 		$2.73K Buy
+25
New +$2.76K ﹤0.01% 429
2021
Q4 		– Sell
-46
Closed -$5K – 502
2021
Q3 		$5K Buy
+46
New +$4.78K ﹤0.01% 335

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Syverson Strege & Co's HZNP Position: Q2 2023 in Review

Syverson Strege & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 25 shares — an estimated $2.73K sold.

Syverson Strege & Co first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $5K in Q3 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • Syverson Strege & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 25 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $2.73K.
  • Syverson Strege & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • Syverson Strege & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5K in Q3 2021.
  • 519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.